Nitroso

N-Nitroso impurities, a class of potent mutagenic and carcinogenic compounds, have emerged as a significant concern in the pharmaceutical industry. These impurities can form during the manufacturing process of active pharmaceutical ingredients (APIs) and drug products, posing severe health risks to patients. As regulatory bodies tighten their guidelines and enforcement measures, pharmaceutical companies are under

N-Nitroso compounds, also known as nitrosamines, are a class of highly potent and mutagenic chemical compounds that have been linked to various types of cancer. These compounds can be formed unintentionally during manufacturing processes or through reactions with nitrite ions and secondary or tertiary amines. Due to their potential health hazards, it is crucial to

In the rapidly advancing pharmaceutical industry, ensuring the safety and efficacy of drugs is essential. A critical focus area is the control of impurities, particularly nitroso impurities, which can impact drug safety. Sumatriptan, a widely prescribed migraine medication, is known to develop a specific nitroso impurity that has raised concerns among regulators and pharmaceutical companies.

Medications play a crucial role in managing various health conditions, from hypertension to attention deficit hyperactivity disorder (ADHD). However, the presence of impurities in these drugs can pose significant risks to patient safety. One such impurity, N-nitroso-clonidine, has recently raised concerns among healthcare professionals and regulatory authorities worldwide. At Aquigen Bio Sciences, the leading Contract